JPRN-jRCTs031210557招募中2 期
A single-arm, phase II study to evaluate the effect of low-dose atovaquone on the prevention of pneumocystis pneumonia in patients with rheumatic diseases treated with corticosteroids
Furuta Syunsuke0 个研究点目标入组 50 人开始时间: 2022年1月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients who meet all of the following criteria are eligible.
- •1) Age 20 years or older (regardless of gender)
- •2) Patients who are scheduled to start, or have started within 10 days of starting, prednisolone at a dose of 0.5 mg/kg/day or higher or equivalent corticosteroids for the treatment of rheumatic diseases.
- •3) Patients who have been fully informed about participation in the study prior to the start of the study and who have provided written consent.
排除标准
- •Patients who meet any of the following criteria should be excluded.
- •1) Patients with a history of continuous use of corticosteroids within 6 months (excluding patients who meet the inclusion criteria 2)
- •2) Patients who are already taking ST combination, atovaquone, pentamidine, or dapsone
- •3) Patients with a history of hypersensitivity to atovaquone
- •4) Patients with uncontrolled complications
- •5) Patients whose AST or ALT exceeds three times the upper limit of the institutional reference value
- •6) Patients who are pregnant, may become pregnant, within 28 days postpartum, or breast-feeding
- •7) Any other patient who is judged by the investigator or sub-investigator to be inappropriate for the safe conduct of the study.
研究者
相似试验
招募中
2 期
on-randomized clinical trial to assess the effect of a medication against cytomegalovirus in patients who are not infected originally cytomegalovirus but who have received renal transplantation from donors that are infected by cytomegalovirus.CMV seronegative patients that have received kidney allografts from CMV seropositive donorsV01-Y98RBR-8gcx9mTheraclone Sciences, Inc
撤回
不适用
A single arm phase II trial to evaluate the efficacy of Poziotinib, pan HER inhibitor in recurrent/metastatic esophageal cancerKCT0003833Yonsei University Health System, Severance Hospital49
尚未招募
2 期
Biomarcer-2 :Biomarker informed optimal management of advanced RAS wild type colorectal cancerAdvanced RAS Wild type right sided Colorectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12623000874617Australasian Gastrointestinal Trials Group29
进行中（未招募）
不适用
A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with metastatic renal cell cancer (Bevacizumab with standard therapy in RCC) - Bevacizumab with standard therapy in RCCMetastatic renal cell cancerEUCTR2005-006161-13-DERoche Pharma AG
进行中（未招募）
1 期
A phase II study of linperlisib (YY-20394) in patients with relapsed or refractory peripheral T/NK cell or Cutaneous T Cell lymphomaCTIS2022-501431-16-00Shanghai Yingli Pharmaceutical Co. Ltd.107